Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Williams Companies Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Williams Companies Inc trades at $72.8 (market cap $91.21B). The key difference: Williams Companies Inc is far larger — about 18.7× Travere Therapeutics Inc. Common Stock's market cap, and Williams Companies Inc pays a 2.82% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Williams Companies Inc for 58 Days on average.
| TVTX | WMB | |
|---|---|---|
Market Cap | $4.88B | $91.21B |
Volume | 1,668,577 | 6,950,661 |
Sector | Health | Energy |
52-Week High | $67.52 | $79.40 |
52-Week Low | $26.79 | $56.51 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $5.01B | $121.84B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Williams Companies (WMB) trades at $72.80, down 1.85% on the day, with strong technical momentum indicated by bullish moving averages. The company maintains robust profitability with 25.18% net income margin and 24.02% ROE, supported by $5.9B operating cash flow in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 and Q2 2026 missed. The stock benefits from positive analyst sentiment with 79% buy ratings and $87.08 consensus price target, representing 20% upside potential.
WMB presents a compelling investment case with strong dividend growth, exposure to rising natural gas demand from AI data centers, and resilient midstream business model. Key risks include energy market volatility, high debt levels at $24.74B long-term debt, and execution challenges in capital-intensive projects. The stock's valuation at 29.71 P/E appears reasonable given growth prospects, but investors should monitor debt management and energy price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
